Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.2% Higher - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price shot up 8.2% on Tuesday . The company traded as high as $4.48 and last traded at $4.42. 12,534,685 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 13,434,642 shares. The stock had previously closed at $4.08.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RXRX. Needham & Company LLC lowered their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Morgan Stanley dropped their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Price Performance

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -2.78 and a beta of 0.99. The company has a fifty day moving average price of $4.95 and a two-hundred day moving average price of $6.43.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the company earned ($0.39) EPS. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth about $36,000. GAMMA Investing LLC increased its stake in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Farther Finance Advisors LLC increased its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after buying an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after acquiring an additional 2,387 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.